论文部分内容阅读
目的比较来氟米特与柳氮磺吡啶分别联合甲氨蝶呤治疗强直性脊柱炎的疗效与安全性。方法将304例强直性脊柱炎患者随机分为A组102例、B组102例及C组100例。A组采用来氟米特联合甲氨蝶呤治疗,B组采用柳氮磺吡啶联合甲氨蝶呤治疗,C组单独应用甲氨蝶呤。比较3组治疗有效率及不良反应发生情况。结果A组和B组的治疗总有效率均高于C组,差异均有统计学意义(P<0.05);A组和B组总有效率比较差异无统计学意义(P>0.05)。A组和B组的不良反应发生率均低于C组,差异有统计学意义(P<0.05);而A组和B组不良反应发生率比较差异无统计学意义(P>0.05)。结论来氟米特与柳氮磺吡啶分别联合甲氨蝶呤治疗强直性脊柱炎,临床疗效均优于单独应用甲氨蝶呤,值得推广应用。
Objective To compare the efficacy and safety of leflunomide combined with sulfasalazine and methotrexate in the treatment of ankylosing spondylitis. Methods 304 patients with ankylosing spondylitis were randomly divided into A group of 102 cases, B group of 102 cases and C group of 100 cases. Group A was treated with leflunomide and methotrexate, group B was treated with sulfasalazine and methotrexate, and group C was given methotrexate alone. Comparison of three groups of treatment efficiency and adverse reactions occurred. Results The total effective rates of group A and group B were significantly higher than those of group C (P <0.05). There was no significant difference in the total effective rate between group A and group B (P> 0.05). The adverse reactions in group A and group B were lower than those in group C (P <0.05), but there was no significant difference in the incidence of adverse reactions between groups A and B (P> 0.05). Conclusion Leflunomide and sulfasalazine combined with methotrexate in the treatment of ankylosing spondylitis, clinical efficacy are superior to methotrexate alone, it is worth promoting the application.